Interferon Gamma Release Assays and Tuberculin Skin Test Performance in Different Settings of HIV Immunodeficiency

Roberto Parrella, Vincenzo Esposito, Mirella Onofrio, Giovanni Parrella, Rosaria Viglietti, Vincenzo Sangiovanni, Miriam Gargiulo, Filomena Di Martino, Annalisa del Giudice, Giulia Santoro, Mariantonio Bernardo, Maria Aurora Carleo and Antonio Chiranni

Abstract. Background/Aim: HIV infection is a risk factor for re-activation of latent tuberculosis infection (LTBI). In recent years new blood tests for the detection of TB infection have been developed: Quantiferon TB Gold in Tube and TSPOT TB, which are interferon-γ releasing assays (IGRAs), have improved the identification of LTBI. In our study we have compared IGRAs and TST in HIV-positive patients with different settings of immunodeficiency. Patients and Methods: 98 consecutive HIV patients were recruited. They underwent a blood draw, a chest radiography and a tuberculin skin test. The HIV infection setting was detected and IGRAs were carried out. Five patients showed a complete correspondence of TST, TSPOT-TB and QFT-IT. Discordant results were observed in patients testing positive to IGRAs but negative to TST. Only 2 patients showed positive TST and negative IGRAs. Conclusion: Our study showed a poor concordance between tuberculin skin test and IGRAs, mainly in patients with a low CD4 cell count.

Medical conditions associated with immunosuppression, such as HIV infection, treatments based on corticosteroids >15 mg/day or tumor necrosis factor antagonists or immunosuppressors drugs after organ transplant, represent a risk factor for progression to active TB and for development of reactivation. Other risk factors are age <5 years old, recent TB infection (in the last 2 years), smoke, drug addiction, chronic diseases such as diabetes and chronic kidney failure (4-6).

The risk of progression from latent to active TB is between 5% and 10% and this risk is greater in the first years after the development of latent infection (6, 7).

People with TB and HIV co-infection are estimated to be 11 million worldwide and in these subjects the risk of progression from latent TB infection to active disease seems to be about 10% annually, which is also the case in patients who receive highly active anti-retroviral therapy (HAART) (7).

Several studies have shown that isoniazid preventive therapy (IPT) as treatment of latent TB infection (LTBI) may reduce the risk of progression to active disease by about 36% and that this risk reduction is about 62% in patients with a positive tuberculin skin test (TST) (8, 10). In order to enhance TB control, it is necessary and urgent to identify and to treat LTBI in HIV patients.

Until recently, TST was the only test available for diagnosing latent TB infection, but this tool has some limitations such as: false-positive results due to exposure to non-tuberculous mycobacteria and to BCG vaccine; false negative results due to impaired cellular immunity; a reader related variability of the results (9).

Certain studies have shown that among HIV patients, the proportion of negative TST is higher than in people without HIV infection (10, 11).

In recent years new blood tests for the detection of TB infection have been developed: Quantiferon TB Gold in Tube (QFT-GIT) and TSPOT TB (T-Spot), that measure the amount of IFN-γ-released from activated T-cells after activation by Mycobacterium tuberculosis (M. tuberculosis) infection.
exposure to \( M. \) \textit{tuberculosis} antigens. Quantiferon determines the level of soluble IFN\( \gamma \) produced, while TSPOT detects the number of IFN\( \gamma \)-producing cells (12, 13).

The antigens used in these tests seem to be more specific than the ones included in Purified Protein Derivative (PPD) and do not cross-react with BCG and \( M. \) \textit{avium} complex. Moreover several studies have shown that IGRAs may be more sensitive than TST in HIV patients for diagnosis of \( M. \) \textit{tuberculosis} infection and less affected by advanced immunosuppression (12-14).

In current literature the data about the performance of the IGRAs in HIV subjects are discordant and limited and few studies compare both IGRAs with TST for diagnosis of LTBI in patients with HIV infection and different grades of immunodeficiency (6, 13, 14).

The aim of the present study was to compare both IGRAs with TST for the diagnosis of latent tuberculosis infection in a cohort of patients with HIV infection and different settings of immunosuppression.

\section*{Patients and Methods}

\subsection*{Patients and samples.}

Patients were recruited into at the 3rd Department of Infectious Diseases, Unit of Pneumology and Unit of Microbiology and Virology at D. Cotugno Hospital- AORN dei Colli in Naples.

All eligible patients were HIV-infected adults (age>20 years) treated from December 2011 to December 2013. At enrollment they gave their written informed consent. The subjects with signs and symptoms related to active TB were considered not eligible. Patients with opportunistic infections and pneumonia were also excluded from the study.

Biochemical, clinical and demographic data, such as age, gender, nationality, sexual attitudes, drug addiction, HIV transmission route, history of HIV infection and contacts with TB cases, incarceration, were recorded in a database and reported on a medical record.

\subsection*{Procedures.}

Blood samples were collected to evaluate immunological and viral status of HIV infection at enrollment (CD4 cell count, CD4 cell nadir and HIV-RNA viral load were detected) and to measure IGRAs tests (Quantiferon TB Gold in Tube- Cellestis Ltd, Australia and T-Spot TB- Oxford Immunotec Ltd), while TST with an intradermal injection of PPD 5 UI (Tubertest- Sanofi Pasteur MSD, SNC). The diameter of induration was measured at 48-72 h and considered positive if equal or higher than 5 mm.

\begin{table}[h]
\centering
\begin{tabular}{|l|c|}
\hline
\textbf{Number of patients} & 98 consecutive HIV positive patients \\
\textbf{Gender} & 88 male/10 female \\
\textbf{MEDIAN age (range)} & 44.4 years (22-77) \\
\textbf{Nationality} & 11 sub Saharan Africa \\
& 4 Eastern Europe \\
& 2 Southern America \\
& 81 Italy \\
\hline
\textbf{Number of NAIVE patients (\%)} & 14 patients (14.2\%) \\
\textbf{Number of patients on haart (\%)} & 84 patients (85.7\%) \\
\textbf{Median CD4 (range)} & 403.8 cells/\mu L (6-1400) \\
\textbf{HIV-RNA, mean\pm SD} & 19\pm 331219.5251 \\
\hline
\end{tabular}
\caption{Demographical and biochemical characteristics of patients included in the study.}
\end{table}

To perform Quantiferon, blood samples from each patient were inoculated in three-1 mL heparinized tubes, one containing a negative control, one containing a positive control (phytohemagglutinin) and one containing TB antigens (ESAT-6, CFP-10, TB7-7). Blood samples were incubated at 37°C for 16-20 h and then IFN\( \gamma \) was quantified by ELISA. The result was considered positive if the levels of IFN\( \gamma \) after stimulation with TB antigens were \( \geq 0.35 \) IU/mL and \( \geq 25\% \) of the negative control. The result was considered positive if IFN\( \gamma \) levels were \( < 0.35 \) IU/mL or \( < 25\% \) of the negative control. The result was indeterminate if the negative control was \( \geq 8.0 \) IU/mL or if the positive control was \( < 0.5 \) IU/mL.

To perform T-SPOT TB, T-Cell Xtend reagent was added to blood samples that were processed 32 h after collection. Peripheral blood mononuclear cells (PBMC) were separated by centrifugation from samples and then placed into four wells. Then the wells were stimulated with phytohemagglutinin (positive control), ESAT-6, CFP-10, AIM V medium (negative control) and incubated for 16-20 h at 37°C. The result was considered positive if the number of spot-forming units was \( \geq 5 \), as well as when spot-forming units were \( > 2x \) spot-forming units of negative control. The result was considered invalid if the positive control was \( < 20 \) spot-forming cells.

\section*{Results}

The three tests were performed in 98 consecutive patients with HIV infection. Demographic, clinical and biochemical characteristics of the patients are shown in Table I. 88\%/98 (89.7\%) of patients were male, 10\%/98 (10.2\%) were female. Median age was 44.4 years (range=22-77). 81\%/98 (82.6\%) of patients came from Italy, 11\%/98 (11.2\%) were from Sub-Saharan Africa, 4\%/98 (4.08\%) from Eastern Europe, 2\%/98 (2.04\%) from Southern America. Median CD4 was 403.8 cells/\mu L (range=6-1400 cells/\mu L).

The number of patients with a CD4 cells count \( < 100 \) (group 1) was 18 (18.3\%). In this group median CD4 was 41.6 (range=22-67 cells/\mu L). The patients with CD4 \( \geq 101 \) and \( \leq 200 \) (group 2) were 9 (9.1\%) and median CD4 was 140.5 (range=111-183 cells/\mu L). The number of patients with CD4 \( \geq 201 \) and \( \leq 300 \) (group 3) was 14 (14.2\%) with median CD4 of 255.4 (range=202-300 cells/\mu L). Patients with CD4\( \geq 301 \) cells/\mu L.
300 (group 4) were 57 (58.1%) and median CD4 was 595.7 (range=304-1400 cells/μL).

TST was positive in 2 patients of group 3 (14.3%) and 5 patients of group 4 (8.8%). It was negative in 14 patients in group 1 (77.8%), 8 patients in group 2 (88.9%), 8 patients in group 3 (57.1%) and 44 patients in group 4 (77.2%). TST wasn’t read in 4 patients of group 1 (22.2%), 1 patient of group 2 (11.1%), 4 patients of group 3 (28.6%) and 8 patients in group 4 (14%).

TSPOT-TB was positive in 1 patient in group 1 (5.5%), 2 patients in group 3 (14.3%) and 9 patients in group 4 (15.8%). The test showed a negative result in 15 patients in group 1 (83.3%), 7 patients in group 2 (77.8%), 11 patients in group 3 (78.6%) and 46 patients in group 4 (80.7%). It was indeterminate in 6 patients in group 1 (11.2%), 2 patients in group 2 (22.2%), 1 patient in group 3 (7.1%) and 4 patients in group 4 (3.5%).

Quantiferon-IT was positive in 1 patient in group 1 (5.6%), 1 patient in group 2 (11.1%), 1 patient in group 3 (7.1%) and 7 patients in group 4 (12.3%). The results were negative in 16 patients of group 1 (88.8%), 7 patients of group 2 (77.8%), 12 patients in group 3 (85.8%) and 49 patients of group 4 (85.9%). It was indeterminate in 1 patient of group 1 (5.6%), 1 patient of group 2 (11.1%), 1 patient of group 3 (7.1%) and 1 patient of group 4 (1.8%) (Figure 1).

Five patients showed a complete correspondence of TST, TSPOT-TB and QFT-IT.

Among patients with a negative TST, 4.1% showed a positive TSPOT-TB and 2.1% had a positive QFT-IT. 9.2% of all patients with a negative TST showed a positive result to IGRAs (Figure 2).

Discordant results were observed in patients testing positive to IGRAs but negative to TST. Only 2 patients showed positive TST and negative IGRAs. Results of the study are summarized in Table II.

**Discussion**

TST, TSPOT-TB and Quantiferon-IT were positive in 7.1%, 12.2%, 10.2% cases respectively. Positive results of the tests seemed to associate with higher CD4 cell counts. Our study showed a poor concordance between TST and IFN-γ releasing assays, mainly in patients with a low CD4 cell count, as already reported by several articles in literature (13-15). The results of our study showed an increase in the number of patients that could undergo the preventive therapy for latent TB infection: among patients with negative TST, 4.1% had a positive TSPOT-TB, 2.1% had a positive QFT-IT; 9.2% patients had positive IGRAs, totally.

IGRAs should be able to identify TST negative subjects who could be treated with isoniazid. Interestingly, in our study, the blood tests provided low proportion of indeterminate results (13 cases for TSPOT-TB, 4 cases for QFT-IT). Most of these results seem to be related to a low CD4 cell count.

The undetectable results of IFN-γ release assays could be considered as “transient” results in patients with advanced immunosuppression.

Our results need to be confirmed by further investigations conducted in a larger number of cases, in order to establish the clinical impact and the effectiveness of dual testing approaches.

---

**Figure 1.** Percentage of positive tests in relation to the number of CD4.

**Figure 2.** Percentage of positive IGRAs with negative TST.
The study was financed by CERIFARC/Regione Campania decree 176 of 03/07/2009 (BURC nr.45 of 20/07/2009) and selected among “Projects for improving of assistance, diagnosis and therapy of HIV infected patients: immunology, co-infection, information and prevention”.

**References**